Trial Profile
Phase I study evaluating the combination of lapatinib + vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 13 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 20 Aug 2007 New trial record.